CMT Summit

We’ve invited Dr. David Walk to join the panel discussion on “Genotype and Phenotype: Managing Symptoms, The Role of Researchers/Clinicians.”

Don’t wait, reserve your spot at the first Patient-Centered CMT Summit!

Leaders in Charcot-Marie-Tooth research need to be progressive visionaries, willing and able to push the boundaries to explore every opportunity available to advance therapeutics and clinical trials for CMT.

Matt Downing, a CMT1A patient, will join HNF’s Founder and CEO Allison Moore in a panel discussion on the good, the bad, and the benefits of participating in a clinical trial.

Advocating for her own health, Kim was able to harness the power of genetic information to devise a treatment plan that not only reduced, but reversed much of her disability with CMT.

Multiple Sclerosis is the most common autoimmune disorder affecting the central nervous system, with more than 2.3 million people affected worldwide.

Hereditary Neuropathy Foundation is hosting the first Patient-Centered Charcot-Marie-Tooth Summit on October 6, 2016 in New York City.

Adding a genetic counselor to your team of healthcare professionals can be a great benefit for CMT patients and their caregivers.

HNF has invited Dr. Gudesblatt to join us as a panelist on “Standard of care and clinical outcome measures to impact the patient and future research” at the Summit.

Dr. Burgess is on the scientific advisory board of the Hereditary Neuropathy Foundation, and also serves on the Cellular and Molecular Biology of Neurodegeneration grant review panel for the National Institutes of Health.